KUALA LUMPUR, June 30 — Biocon Biologics Ltd (BBL), a fully integrated global biosimilars company, today announced that its Malaysian subsidiary, Biocon Sdn Bhd, has surpassed the milestone of supplying 100 million cartridges of recombinant human insulin (rh-insulin) to the Ministry of Health (MOH).
This achievement reinforces Biocon Biologics’ long-standing commitment to advancing diabetes care and ensuring affordable access to insulin across the country.
Since entering the Malaysian market in 2016, Biocon Biologics has played a pivotal role in transforming diabetes management, and has supplied over 100 million cartridges of rh-insulin serving over 345,000 patients.
Biocon Biologics’ public-private partnership with the Malaysian government exemplifies a successful model for building a resilient biotech ecosystem by driving innovation, developing local talent, enabling better patient outcomes, and advancing insulin self-sufficiency in Malaysia.
Susheel Umesh, Chief Commercial Officer, Biocon Biologics, said: “Expanding access to over 345,000 diabetes patients in Malaysia by providing over 100 million cartridges of rh-insulin reinforces our commitment to equitable diabetes care.
“Every cartridge we produce at our state-of-the-art facility in Johor is a lifeline for someone living with diabetes.
“Our partnership with the MOH and Duopharma underlines how local manufacturing and global expertise can come together to create scalable, sustainable healthcare solutions for patients.”
Leonard Ariff Abdul Shatar, Group Managing Director, Duopharma Biotech Berhad, said: “This significant milestone truly underscores the strength of our enduring, multi-year partnership with Biocon Biologics, an impactful collaboration that aligns with Duopharma Biotech’s vision to ‘Provide Smarter Solutions for a Healthier Life’.
“Through our joint efforts, we are committed to elevating diabetes care across Malaysia, ensuring consistent access to affordable, high-quality insulin. We proudly support the Ministry of Health in strengthening national healthcare resilience, and improving the lives of Malaysians living with diabetes.”
Globally, Biocon Biologics is among the Top Three players for rh-Insulin and Insulin Glargine. In collaboration with its commercial partner Duopharma Marketing Sdn Bhd, a subsidiary of Malaysia’s leading pharmaceutical company Duopharma Biotech Bhd, Biocon Biologics has supported diabetes care across Malaysia since 2016.
Biocon Biologics has established a Centre of Excellence for insulins at its state-of-the-art manufacturing facility in Johor, with a cumulative investment of US$600 million since 2011.
The facility is equipped with end-to-end capabilities to produce a broad portfolio of insulins–regular, basal, and rapid–in multiple presentations including cartridges and delivery devices. The Malaysia Book of Records has recognised Biocon Sdn Bhd as the first and largest integrated insulin manufacturer in Malaysia.
Biocon Biologics is committed to serve one in five insulin-dependent people worldwide and has provided 9.2 billion doses of rh-Insulin and Insulin Glargine cumulatively to patients across the globe.
